Abstract
Valvular heart disease remains common in industrialized countries, because the decrease in prevalence of rheumatic heart diseases has been accompanied by an increase in that of degenerative valve diseases. Aortic stenosis and mitral regurgitation are the two most common types of valvular disease in Europe. The prevalence of valvular disease increases sharply with age, owing to the predominance of degenerative etiologies. The burden of heart valve disease in the elderly has an important impact on patient management, given the high frequency of comorbidity and the increased risk associated with intervention in this age group. Endocarditis is an important etiology of valvular disease and is most commonly caused by Staphylococci. Rheumatic heart disease remains prevalent in developing countries.
Key Points
-
The prevalence of valvular heart disease is estimated at 2.5% in the US population and sharply increases after the age of 65 years owing to the predominance of degenerative etiologies
-
The term 'degenerative' valvular disease relates to a heterogeneous group of conditions the main characteristic of which is an increase in prevalence with age, rendering decision-making for interventions complex
-
Rheumatic heart disease remains common in developing countries, where its prevalence is underestimated by clinical examination and is estimated at 2–3% when using systematic echocardiographic screening
-
Patients who have previously undergone surgery account for almost a third of those referred for the management of valvular disease
-
The proportion of valvular surgeries has increased over the past decade and these procedures now account for more than 20% of all cardiac surgeries
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Soler-Soler, J. & Galve, E. Worldwide perspective of valve disease. Heart 83, 721–725 (2000).
Carapetis, J. R., Steer, A. C., Mulholland, E. K. & Weber, M. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5, 685–694 (2005).
Vahanian, A. et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur. Heart J. 28, 230–268 (2007).
Bonow, R. O. et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 52, e1–e142 (2008).
Desjardins, V. A., Enriquez-Sarano, M., Tajik, A. J., Bailey, K. R. & Seward, J. B. Intensity of murmurs correlates with severity of valvular regurgitation. Am. J. Med. 100, 149–156 (1996).
Baumgartner, H. et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur. J. Echocardiogr. 10, 1–25 (2009).
Lancellotti, P. et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease). Eur. J. Echocardiogr. 11, 223–244 (2010).
Lancellotti, P. et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur. J. Echocardiogr. 11, 307–332 (2010).
Nkomo, V. T. et al. Burden of valvular heart diseases: a population-based study. Lancet 368, 1005–1011 (2006).
Iung, B. et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur. Heart J. 24, 1231–1243 (2003).
Iung, B. et al. Valvular heart disease in the community: a European experience. Curr. Probl. Cardiol. 32, 609–661 (2007).
Zoghbi, W. A. et al. for the American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J. Am. Soc. Echocardiogr. 16, 777–802 (2003).
Hull, M. C., Morris, C. G., Pepine, C. J. & Mendenhall, N. P. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 290, 2831–2837 (2003).
Droogmans, S., Kerkhove, D., Cosyns, B. & Van Camp, G. Role of echocardiography in toxic heart valvulopathy. Eur. J. Echocardiogr. 10, 467–476 (2009).
Kamblock, J. et al. Acute severe mitral regurgitation during first attacks of rheumatic fever: clinical spectrum, mechanisms and prognostic factors. J. Heart Valve Dis. 14, 440–446 (2005).
Tibazarwa, K. B., Volmink, J. A. & Mayosi, B. M. Incidence of acute rheumatic fever in the world: a systematic review of population-based studies. Heart 94, 1534–1540 (2008).
Carapetis, J. R., Currie, B. J. & Mathews, J. D. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population? Epidemiol. Infect. 124, 239–244 (2000).
Kaplan, E. L. Pathogenesis of acute rheumatic fever and rheumatic heart disease: evasive after half a century of clinical, epidemiological, and laboratory investigation. Heart 91, 3–4 (2005).
Rizvi, S. F. et al. Status of rheumatic heart disease in rural Pakistan. Heart 90, 394–399 (2004).
Carapetis, J. R. Rheumatic heart disease in Asia. Circulation 118, 2748–2753 (2008).
McLaren, M. J. et al. Epidemiology of rheumatic heart disease in black shcoolchildren of Soweto, Johannesburg. BMJ 3, 474–478 (1975).
Essop, M. R. & Nkomo, V. T. Rheumatic and nonrheumatic valvular heart disease: epidemiology, management, and prevention in Africa. Circulation 112, 3584–3591 (2005).
Marijon, E. et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N. Engl. J. Med. 357, 470–476 (2007).
Bouma, B. J. et al. To operate or not on elderly patients with aortic stenosis: the decision and its consequences. Heart 82, 143–148 (1999).
Stewart, B. F. et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J. Am. Coll.Cardiol. 29, 630–634 (1997).
Lindroos, M., Kupari, M., Heikkilä, J. & Tilvis, R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J. Am. Coll. Cardiol. 21, 1220–1225 (1993).
Iung, B. Management of the elderly patient with aortic stenosis. Heart 94, 519–524 (2008).
Probst, V. et al. Familial aggregation of calcific aortic valve stenosis in the western part of France. Circulation 113, 856–860 (2006).
Parolari, A. et al. Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention. Eur. J. Cardiothorac. Surg. 35, 493–504 (2009).
Cosmi, J. E. et al. The risk of the development of aortic stenosis in patients with “benign” aortic valve thickening. Arch. Intern. Med. 162, 2345–2347 (2002).
Chan, K. L., Ghani, M., Woodend, K. & Burwash, I. G. Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve. Am. J. Cardiol. 88, 690–693 (2001).
Palta, S., Pai, A. M., Gill, K. S. & Pai, R. G. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 101, 2497–2502 (2000).
Lester, S. J. et al. Rate of change in aortic valve area during a cardiac cycle can predict the rate of hemodynamic progression of aortic stenosis. Circulation 101, 1947–1952 (2000).
Rossebø, A. B. et al. for the SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359, 1343–1356 (2008).
Chan, K. L., Teo, K., Dumesnil, J. G., Ni, A. & Tam, J. for the ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 121, 306–314 (2010).
Cowell, S. J. et al. for the SALTIRE Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 352, 2389–2397 (2005).
Garg, V. et al. Mutations in NOTCH1 cause aortic valve disease. Nature 437, 270–274 (2005).
Tutar, E., Ekici, F., Atalay, S. & Nacar, N. The prevalence of bicuspid aortic valve in newborns by echocardiographic screening. Am. Heart J. 150, 513–515 (2005).
Nistri, S., Basso, C., Marzari, C., Mormino, P. & Thiene, G. Frequency of bicuspid aortic valve in young male conscripts by echocardiogram. Am. J. Cardiol. 96, 718–721 (2005).
Lloyd-Jones, D. et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation 121, e46–e215 (2010).
Tzemos, N. et al. Outcomes in adults with bicuspid aortic valves. JAMA 300, 1317–1325 (2008).
Michelena, H. I. et al. Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community. Circulation 117, 2776–2784 (2008).
Roberts, W. C. & Ko, J. M. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 111, 920–925 (2005).
Sievers, H. H. & Schmidtke, C. A classification system for the bicuspid aortic valve from 304 surgical specimens. J. Thorac. Cardiovasc. Surg. 133, 1226–1233 (2007).
Davies, R. R. et al. Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann. Thorac. Surg. 83, 1338–1344 (2007).
Dare, A. J., Veinot, J. P., Edwards, W. D., Tazelar, H. D & Schaff, H. V. New observations on the etiology of aortic valve disease: a surgical pathologic study of 236 cases from 1990. Hum. Pathol. 24, 1330–1338 (1993).
Borer, J. S. et al. Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance. Circulation 97, 525–534 (1998).
Singh, J. P. et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am. J. Cardiol. 83, 897–902 (1999).
Reid, C. L., Anton-Culver, H., Yunis, C. & Gardin, J. M. Prevalence and clinical correlates of isolated mitral, isolated aortic regurgitation, and both in adults aged 21 to 35 years (from the CARDIA study). Am. J. Cardiol. 99, 830–834 (2007).
Underwood, M. J., El Khoury, G., Deronck, D., Glineur, D. & Dion, R. The aortic root: structure, function, and surgical reconstruction. Heart 83, 376–380 (2000).
le Polain de Waroux, J. B. et al. Functional anatomy of aortic regurgitation: accuracy, prediction of surgical repairability, and outcome implications of transesophageal echocardiography. Circulation 116, I264–I269 (2007).
Padial, L. R. et al. Doppler echocardiographic assessment of progression of aortic regurgitation. Am. J. Cardiol. 80, 306–314 (1997).
Roberts, W. C., Ko, J. M., Moore, T. R. & Jones, W. H. 3rd Causes of pure aortic regurgitation in patients having isolated aortic valve replacement at a single US tertiary hospital (1993 to 2005). Circulation 114, 422–429 (2006).
Chandrashekhar, Y., Westaby, S. & Narula, J. Mitral stenosis. Lancet 374, 1271–1283 (2009).
Gordon, S. P., Douglas, P. S., Come, P. C. & Manning, W. J. Two-dimensional and Doppler echocardiographic determinants of the natural history of mitral valve narrowing in patients with rheumatic mitral stenosis: implications for follow-up. J. Am. Coll. Cardiol. 19, 968–973 (1992).
Abdel-Hady, E. S. et al. Maternal and perinatal outcome of pregnancies complicated by cardiac disease. Int. J. Gynaecol. Obstet. 90, 21–25 (2005).
Pressman, G. S., Agarwal, A., Braitman, L. E. & Muddassir, S. M. Mitral annular calcium causing mitral stenosis. Am. J. Cardiol. 105, 389–391 (2010).
Croft, L. B. et al. Age-related prevalence of cardiac valvular abnormalities warranting infectious endocarditis prophylaxis. Am. J. Cardiol. 94, 386–389 (2004).
Avierinos, J. F. et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 106, 1355–1361 (2002).
Freed, L. A. et al. Prevalence and clinical outcome of mitral-valve prolapse. N. Engl. J. Med. 341, 1–7 (1999).
Rabkin, E. et al. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 104, 2525–2532 (2001).
Barber, J. E. et al. Mechanical properties of myxomatous mitral valves. J. Thorac. Cardiovasc. Surg. 122, 955–962 (2001).
Kyndt, F. et al. Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. Circulation 115, 40–49 (2007).
Avierinos, J. F., Detaint, D., Messika-Zeitoun, D., Mohty, D. & Enriquez-Sarano, M. Risk, determinants, and outcome implications of progression of mitral regurgitation after diagnosis of mitral valve prolapse in a single community. Am. J. Cardiol. 101, 662–667 (2008).
Barasch, E. et al. Clinical significance of calcification of the fibrous skeleton of the heart and aortosclerosis in community dwelling elderly. The Cardiovascular Health Study (CHS). Am. Heart J. 151, 39–47 (2006).
Bursi, F. et al. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. Circulation 111, 295–301 (2005).
Grigioni, F., Enriquez-Sarano, M., Zehr, K. J., Bailey, K. R. & Tajik, A. J. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 103, 1759–1764 (2001).
Møller, J. E. et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 112, 3320–3327 (2005).
Hoen, B. et al. for the AEPEI Study Group. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA 288, 75–81 (2002).
Tleyjeh, I. M. et al. A systematic review of population-based studies of infective endocarditis. Chest 132, 1025–1035 (2007).
Murdoch, D. R. et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch. Intern. Med. 169, 463–473 (2009).
Tornos, P. et al. Infective endocarditis in Europe: lessons from the Euro Heart Survey. Heart 91, 571–575 (2005).
Sy, R. W. & Kritharides, L. Health care exposure and age in infective endocarditis: results of a contemporary population-based profile of 1,536 patients in Australia. Eur. Heart J. 31, 1890–1897 (2010).
Duval, X. & Leport, C. Prophylaxis of infective endocarditis: current tendencies, continuing controversies. Lancet Infect. Dis. 8, 225–232 (2008).
Habib, G. et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur. Heart J. 30, 2369–2413 (2009).
The Society of Thoracic Surgeons. Adult Cardiac Surgery Database, Executive Summary, 10 years STS report—period ending 12/31/2009 [online], (2010).
Brown, J. M. et al. Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J. Thorac. Cardiovasc. Surg. 137, 82–90 (2009).
Gammie, J. S. et al. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann. Thorac. Surg. 87, 1431–1437 (2009).
Vahanian, A. & Palacios, I. F. Percutaneous approaches to valvular disease. Circulation 109, 1572–1579 (2004).
Iung, B. et al. Temporal trends in percutaneous mitral commissurotomy over a 15-year period. Eur. Heart J. 25, 701–707 (2004).
Marijon, E. et al. What are the differences in presentation of candidates for percutaneous mitral commissurotomy across the world and do they influence the results of the procedure? Arch. Cardiovasc. Dis. 101, 611–617 (2008).
Rodés-Cabau, J. et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J. Am. Coll. Cardiol. 55, 1080–1090 (2010).
Thomas, M. et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: A European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 122, 62–69 (2010).
Himbert, D. et al. Results of transfemoral or transapical aortic valve implantation following a uniform assessment in high-risk patients with aortic stenosis. J. Am. Coll. Cardiol. 54, 303–311 (2009).
Vahanian, A. et al. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European association of cardio-thoracic surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EuroIntervention 4, 193–199 (2008).
Feldman, T. et al. for the EVEREST Investigators. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J. Am. Coll. Cardiol. 54, 686–694 (2009).
Author information
Authors and Affiliations
Contributions
B. Iung researched data for the article, contributed to the discussion of content, wrote the article, and reviewed and edited the manuscript before submission and after peer review. A. Vahanian contributed to the discussion of content, and reviewed and edited the manuscript before submission and after peer review.
Corresponding author
Ethics declarations
Competing interests
B. Iung has acted as a Consultant for Boehringer-Ingelheim and Servier, and he has received Speakers' Bureau honoraria from Edwards Lifesciences, St. Jude Medical, and Valtech. A. Vahanian has acted as a Consultant for Edwards Lifesciences and Medtronic and he has received Speakers' Bureau honoraria from Abbott and Valtech.
Rights and permissions
About this article
Cite this article
Iung, B., Vahanian, A. Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol 8, 162–172 (2011). https://doi.org/10.1038/nrcardio.2010.202
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2010.202
This article is cited by
-
Low-flow in aortic valve stenosis patients with reduced ejection fraction does not depend on left ventricular function
Clinical Research in Cardiology (2024)
-
Aortic regurgitation is associated with African American and Asian race, smoking, renal disease, and numerous autoimmune diseases in addition to traditional cardiovascular risk factors but has lower risk with alcohol intake
Clinical Research in Cardiology (2024)
-
Multi-center retrospective cohort study applying deep learning to electrocardiograms to identify left heart valvular dysfunction
Communications Medicine (2023)
-
Towards Longitudinal Monitoring of Leaflet Mobility in Prosthetic Aortic Valves via In-Situ Pressure Sensors: In-Silico Modeling and Analysis
Cardiovascular Engineering and Technology (2023)
-
Analysis of local extracellular matrix identifies different aetiologies behind bicuspid and tricuspid aortic valve degeneration and suggests therapies
Cellular and Molecular Life Sciences (2023)